Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
on behalf of the PanACEA consortium, Koele, S. E., Stoycheva, K., Mtweve, C., Manyama, C., Mpagama, S., Mhimbira, F., Wallis, R., Ntinginya, N. E., Liyoyo, A., Huglin, B., Minja, L. T., Wagnerberger, L., Zumba, T., Noreña, I., Peter, D. D., Beattie, T., Makkan, H., Sloan, D. J. & Brake, L. T.
& 31 others,
Aarnoutse, R. E., McHugh, T. D., Wildner, L., Schildkraut, J., Aldana, B. H., Phillips, P. P. J., Hoelscher, M., Svensson, E. M., Heinrich, N., Dreisbach, J., Gross-Demel, P., Hoffmann, L., Heinrich, N., Razid, A., Lutchmun, W., Dierig, A., Jarchow-MacDonald, A., Norena, I., Paramo, L., Sloan, D., Sabiiti, W., Gillespie, S., te Brake, L., Svensson, E., Mouhdad, C., Koele, S., Aarnoutse, R., Boeree, M., Adegbite, B. R., Grobusch, M. P. & Grobusch, M. P.,
1 Aug 2025,
In: Journal of Antimicrobial Chemotherapy. 80,
8,
p. 2305-2313 9 p.Research output: Contribution to journal › Article › Academic › peer-review
